Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| REGENERON PHARMACEUTICALS, INC.REGN · Entity 2010 | Director | April 03, 2023 | April 05, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
REGENERON PHARMACEUTICALS, INC.
Report date April 03, 2023 · Filed April 05, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Indirectby CLAT | 125,493 |
Reported balance
After 2023-04-03 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2023-04-03 · Gift · Disposed 259 · Balance 125,493 |
| Common StockSEC Table I · non-derivative | Direct | 312,578 |
Reported balance
Holding disclosure · report date 2023-04-03 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 312,578 |
| Common StockSEC Table I · non-derivative | IndirectBy 401(k) Plan | 1,963 |
Reported balance
Holding disclosure · report date 2023-04-03 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 1,963 |
| Common StockSEC Table I · non-derivative | Indirectby Spouse as Trustee | 23,461 |
Reported balance
Holding disclosure · report date 2023-04-03 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 23,461 |
| Common StockSEC Table I · non-derivative | Indirectby trust for grandch | 3,609 |
Reported balance
Holding disclosure · report date 2023-04-03 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 3,609 F1: By trusts for the benefit of nine grandchildren of the reporting person, each of which holds 401 shares of Company stock. The reporting person and/or the spouse of the reporting person is the trustee of each such trust. |
Filing footnotes · ownership attribution and instrument terms
F1: By trusts for the benefit of nine grandchildren of the reporting person, each of which holds 401 shares of Company stock. The reporting person and/or the spouse of the reporting person is the trustee of each such trust.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 10, 2018 Filed Jul 11, 2018 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 6,405 | $367.40 | $2,353,197.00 |
DisclosureSEC source: 0001708138-18-000013 · edgardoc.xml · nonDerivative · entry 6 VAGELOS P ROY · CIK 0001013064 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 425,652 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F5 · price: Represents volume-weighted average price of sales of 6,405 shares of Company stock on July 10, 2018 at prices ranging from $367.02 to $367.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on July 10, 2018 at each separate price. Read SEC document |
| July 10, 2018 Filed Jul 11, 2018 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 24,339 | $366.49 | $8,920,000.11 |
DisclosureSEC source: 0001708138-18-000013 · edgardoc.xml · nonDerivative · entry 5 VAGELOS P ROY · CIK 0001013064 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 432,057 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F4 · price: Represents volume-weighted average price of sales of 24,339 shares of Company stock on July 10, 2018 at prices ranging from $366.00 to $366.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on July 10, 2018 at each separate price. Read SEC document |
| July 10, 2018 Filed Jul 11, 2018 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 17,221 | $365.56 | $6,295,308.76 |
DisclosureSEC source: 0001708138-18-000013 · edgardoc.xml · nonDerivative · entry 4 VAGELOS P ROY · CIK 0001013064 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 456,396 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F3 · price: Represents volume-weighted average price of sales of 17,221 shares of Company stock on July 10, 2018 at prices ranging from $365.05 to $365.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on July 10, 2018 at each separate price. Read SEC document |
| July 10, 2018 Filed Jul 11, 2018 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 900 | $364.75 | $328,275.00 |
DisclosureSEC source: 0001708138-18-000013 · edgardoc.xml · nonDerivative · entry 3 VAGELOS P ROY · CIK 0001013064 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 473,617 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F2 · price: Represents volume-weighted average price of sales of 900 shares of Company stock on July 10, 2018 at prices ranging from $364.73 to $364.83. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on July 10, 2018 at each separate price. Read SEC document |
| July 09, 2018 Filed Jul 11, 2018 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 153,274 | $0.00 Strike: $16.80 | $0.00 |
DisclosureSEC source: 0001708138-18-000013 · edgardoc.xml · derivative · entry 15 VAGELOS P ROY · CIK 0001013064 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 153,274 shares Expires 2018-12-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F10 · derivative.exercise_date: The stock option award (combined incentive stock option and non-qualified stock option) vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| July 09, 2018 Filed Jul 11, 2018 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 78,604 | $370.52 | $29,124,354.08 |
DisclosureSEC source: 0001708138-18-000013 · edgardoc.xml · nonDerivative · entry 2 VAGELOS P ROY · CIK 0001013064 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 474,517 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| July 09, 2018 Filed Jul 11, 2018 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 153,274 | $16.80 | $2,575,003.20 |
DisclosureSEC source: 0001708138-18-000013 · edgardoc.xml · nonDerivative · entry 1 VAGELOS P ROY · CIK 0001013064 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 553,121 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| July 06, 2018 Filed Jul 11, 2018 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GiftCommon Stock | 610 | $0.00 | $0.00 |
DisclosureSEC source: 0001708138-18-000013 · edgardoc.xml · nonDerivative · entry 11 VAGELOS P ROY · CIK 0001013064 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Indirect · by CLAT Disclosed balance after: 147,934 Read SEC document |
| June 21, 2018 Filed Jun 22, 2018 20:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 200 | $336.87 | $67,374.00 |
DisclosureSEC source: 0001708138-18-000009 · edgardoc.xml · nonDerivative · entry 15 VAGELOS P ROY · CIK 0001013064 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 399,847 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| June 21, 2018 Filed Jun 22, 2018 20:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 300 | $335.01 | $100,503.00 |
DisclosureSEC source: 0001708138-18-000009 · edgardoc.xml · nonDerivative · entry 14 VAGELOS P ROY · CIK 0001013064 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,047 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F12 · price: Represents volume-weighted average price of sales of 300 shares of Company stock on June 21, 2018 at prices ranging from $335.00 to $335.01. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 21, 2018 at each separate price. Read SEC document |
| June 21, 2018 Filed Jun 22, 2018 20:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 500 | $333.15 | $166,575.00 |
DisclosureSEC source: 0001708138-18-000009 · edgardoc.xml · nonDerivative · entry 13 VAGELOS P ROY · CIK 0001013064 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,347 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F11 · price: Represents volume-weighted average price of sales of 500 shares of Company stock on June 21, 2018 at prices ranging from $333.01 to $333.28. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 21, 2018 at each separate price. Read SEC document |
| June 21, 2018 Filed Jun 22, 2018 20:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,300 | $332.80 | $432,640.00 |
DisclosureSEC source: 0001708138-18-000009 · edgardoc.xml · nonDerivative · entry 12 VAGELOS P ROY · CIK 0001013064 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,847 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F10 · price: Represents volume-weighted average price of sales of 1,300 shares of Company stock on June 21, 2018 at prices ranging from $332.40 to $332.94. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 21, 2018 at each separate price. Read SEC document |
| June 21, 2018 Filed Jun 22, 2018 20:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 100 | $331.09 | $33,109.00 |
DisclosureSEC source: 0001708138-18-000009 · edgardoc.xml · nonDerivative · entry 11 VAGELOS P ROY · CIK 0001013064 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 402,147 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| June 21, 2018 Filed Jun 22, 2018 20:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 3,096 | $330.32 | $1,022,670.72 |
DisclosureSEC source: 0001708138-18-000009 · edgardoc.xml · nonDerivative · entry 10 VAGELOS P ROY · CIK 0001013064 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 402,247 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F9 · price: Represents volume-weighted average price of sales of 3,096 shares of Company stock on June 21, 2018 at prices ranging from $330.00 to $330.92. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 21, 2018 at each separate price. Read SEC document |
| June 21, 2018 Filed Jun 22, 2018 20:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 12,854 | $329.51 | $4,235,521.54 |
DisclosureSEC source: 0001708138-18-000009 · edgardoc.xml · nonDerivative · entry 9 VAGELOS P ROY · CIK 0001013064 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 405,343 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F8 · price: Represents volume-weighted average price of sales of 12,854 shares of Company stock on June 21, 2018 at prices ranging from $329.00 to $329.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 21, 2018 at each separate price. Read SEC document |
| June 21, 2018 Filed Jun 22, 2018 20:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 12,426 | $328.45 | $4,081,319.70 |
DisclosureSEC source: 0001708138-18-000009 · edgardoc.xml · nonDerivative · entry 8 VAGELOS P ROY · CIK 0001013064 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 418,197 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F7 · price: Represents volume-weighted average price of sales of 12,426 shares of Company stock on June 21, 2018 at prices ranging from $328.00 to $328.96. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 21, 2018 at each separate price. Read SEC document |
| June 21, 2018 Filed Jun 22, 2018 20:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 19,393 | $327.48 | $6,350,819.64 |
DisclosureSEC source: 0001708138-18-000009 · edgardoc.xml · nonDerivative · entry 7 VAGELOS P ROY · CIK 0001013064 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 430,623 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F6 · price: Represents volume-weighted average price of sales of 19,393 shares of Company stock on June 21, 2018 at prices ranging from $327.00 to $327.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 21, 2018 at each separate price. Read SEC document |
| June 21, 2018 Filed Jun 22, 2018 20:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 15,594 | $326.57 | $5,092,532.58 |
DisclosureSEC source: 0001708138-18-000009 · edgardoc.xml · nonDerivative · entry 6 VAGELOS P ROY · CIK 0001013064 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 450,016 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F5 · price: Represents volume-weighted average price of sales of 15,594 shares of Company stock on June 21, 2018 at prices ranging from $326.00 to $326.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 21, 2018 at each separate price. Read SEC document |
| June 21, 2018 Filed Jun 22, 2018 20:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 8,047 | $325.67 | $2,620,666.49 |
DisclosureSEC source: 0001708138-18-000009 · edgardoc.xml · nonDerivative · entry 5 VAGELOS P ROY · CIK 0001013064 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 465,610 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F4 · price: Represents volume-weighted average price of sales of 8,047 shares of Company stock on June 21, 2018 at prices ranging from $325.05 to $325.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 21, 2018 at each separate price. Read SEC document |
| June 21, 2018 Filed Jun 22, 2018 20:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 500 | $324.18 | $162,090.00 |
DisclosureSEC source: 0001708138-18-000009 · edgardoc.xml · nonDerivative · entry 4 VAGELOS P ROY · CIK 0001013064 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 473,657 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F3 · price: Represents volume-weighted average price of sales of 500 shares of Company stock on June 21, 2018 at prices ranging from $324.16 to $324.23. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 21, 2018 at each separate price. Read SEC document |
| June 21, 2018 Filed Jun 22, 2018 20:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 400 | $323.97 | $129,588.00 |
DisclosureSEC source: 0001708138-18-000009 · edgardoc.xml · nonDerivative · entry 3 VAGELOS P ROY · CIK 0001013064 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 474,157 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F2 · price: Represents volume-weighted average price of sales of 400 shares of Company stock on June 21, 2018 at prices ranging from $323.96 to $323.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 21, 2018 at each separate price. Read SEC document |
| June 20, 2018 Filed Jun 22, 2018 20:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 153,274 | $0.00 Strike: $16.80 | $0.00 |
DisclosureSEC source: 0001708138-18-000009 · edgardoc.xml · derivative · entry 21 VAGELOS P ROY · CIK 0001013064 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 153,274 Underlying: Common Stock · 153,274 shares Expires 2018-12-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F14 · derivative.exercise_date: The stock option award (combined incentive stock option and non-qualified stock option) vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| June 20, 2018 Filed Jun 22, 2018 20:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 78,564 | $333.07 | $26,167,311.48 |
DisclosureSEC source: 0001708138-18-000009 · edgardoc.xml · nonDerivative · entry 2 VAGELOS P ROY · CIK 0001013064 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 474,557 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| June 20, 2018 Filed Jun 22, 2018 20:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 153,274 | $16.80 | $2,575,003.20 |
DisclosureSEC source: 0001708138-18-000009 · edgardoc.xml · nonDerivative · entry 1 VAGELOS P ROY · CIK 0001013064 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 553,121 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| April 02, 2018 Filed Jun 22, 2018 20:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GiftCommon Stock | 616 | $0.00 | $0.00 |
DisclosureSEC source: 0001708138-18-000009 · edgardoc.xml · nonDerivative · entry 17 VAGELOS P ROY · CIK 0001013064 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Indirect · by CLAT Disclosed balance after: 148,544 Read SEC document |
| January 02, 2018 Filed Jun 22, 2018 20:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GiftCommon Stock | 557 | $0.00 | $0.00 |
DisclosureSEC source: 0001708138-18-000009 · edgardoc.xml · nonDerivative · entry 16 VAGELOS P ROY · CIK 0001013064 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Indirect · by CLAT Disclosed balance after: 149,160 Read SEC document |
| December 12, 2017 Filed Dec 13, 2017 21:53 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 74,390 | $0.00 Strike: $378.98 | $0.00 |
DisclosureSEC source: 0001237899-17-000028 · edgardoc.xml · derivative · entry 10 VAGELOS P ROY · CIK 0001013064 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,390 Underlying: Common Stock · 74,390 shares Expires 2027-12-12 F4 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| December 11, 2017 Filed Dec 13, 2017 21:53 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 153,969 | $0.00 Strike: $21.92 | $0.00 |
DisclosureSEC source: 0001237899-17-000028 · edgardoc.xml · derivative · entry 9 VAGELOS P ROY · CIK 0001013064 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 153,969 shares Expires 2017-12-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F3 · derivative.exercise_date: The stock option award (combined incentive stock option and non-qualified stock option) vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| December 11, 2017 Filed Dec 13, 2017 21:53 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 74,860 | $383.29 | $28,693,089.40 |
DisclosureSEC source: 0001237899-17-000028 · edgardoc.xml · nonDerivative · entry 3 VAGELOS P ROY · CIK 0001013064 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 399,847 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| December 11, 2017 Filed Dec 13, 2017 21:53 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 8,805 | $383.29 | $3,374,868.45 |
DisclosureSEC source: 0001237899-17-000028 · edgardoc.xml · nonDerivative · entry 2 VAGELOS P ROY · CIK 0001013064 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 474,707 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| December 11, 2017 Filed Dec 13, 2017 21:53 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 153,969 | $21.92 | $3,375,000.48 |
DisclosureSEC source: 0001237899-17-000028 · edgardoc.xml · nonDerivative · entry 1 VAGELOS P ROY · CIK 0001013064 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 483,512 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| November 07, 2017 Filed Dec 13, 2017 21:53 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GiftCommon Stock | 91 | $0.00 | $0.00 |
DisclosureSEC source: 0001237899-17-000028 · edgardoc.xml · nonDerivative · entry 5 VAGELOS P ROY · CIK 0001013064 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Indirect · by CLAT Disclosed balance after: 149,717 Read SEC document |
| October 03, 2017 Filed Dec 13, 2017 21:53 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GiftCommon Stock | 477 | $0.00 | $0.00 |
DisclosureSEC source: 0001237899-17-000028 · edgardoc.xml · nonDerivative · entry 4 VAGELOS P ROY · CIK 0001013064 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Indirect · by CLAT Disclosed balance after: 149,808 Read SEC document |
| August 22, 2017 Filed Aug 23, 2017 20:21 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 106 | $483.00 | $51,198.00 |
DisclosureSEC source: 0001708138-17-000017 · edgardoc.xml · nonDerivative · entry 17 VAGELOS P ROY · CIK 0001013064 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 329,543 Read SEC document |
| August 22, 2017 Filed Aug 23, 2017 20:21 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 400 | $482.72 | $193,088.00 |
DisclosureSEC source: 0001708138-17-000017 · edgardoc.xml · nonDerivative · entry 16 VAGELOS P ROY · CIK 0001013064 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 329,649 Read SEC document |
| August 22, 2017 Filed Aug 23, 2017 20:21 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 4,661 | $481.37 | $2,243,665.57 |
DisclosureSEC source: 0001708138-17-000017 · edgardoc.xml · nonDerivative · entry 15 VAGELOS P ROY · CIK 0001013064 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 330,049 F15 · price: Represents volume-weighted average price of sales of 4,661 shares of Company stock on August 22, 2017 at prices ranging from $481.00 to $481.95. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 22, 2017 at each separate price. Read SEC document |
| August 22, 2017 Filed Aug 23, 2017 20:21 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 5,250 | $480.62 | $2,523,255.00 |
DisclosureSEC source: 0001708138-17-000017 · edgardoc.xml · nonDerivative · entry 14 VAGELOS P ROY · CIK 0001013064 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 334,710 F14 · price: Represents volume-weighted average price of sales of 5,250 shares of Company stock on August 22, 2017 at prices ranging from $480.06 to $480.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 22, 2017 at each separate price. Read SEC document |
| August 22, 2017 Filed Aug 23, 2017 20:21 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 600 | $479.63 | $287,778.00 |
DisclosureSEC source: 0001708138-17-000017 · edgardoc.xml · nonDerivative · entry 13 VAGELOS P ROY · CIK 0001013064 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 339,960 F13 · price: Represents volume-weighted average price of sales of 600 shares of Company stock on August 22, 2017 at prices ranging from $479.00 to $479.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 22, 2017 at each separate price. Read SEC document |
| August 22, 2017 Filed Aug 23, 2017 20:21 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,600 | $478.51 | $765,616.00 |
DisclosureSEC source: 0001708138-17-000017 · edgardoc.xml · nonDerivative · entry 12 VAGELOS P ROY · CIK 0001013064 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 340,560 F12 · price: Represents volume-weighted average price of sales of 1,600 shares of Company stock on August 22, 2017 at prices ranging from $478.10 to $478.93. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 22, 2017 at each separate price. Read SEC document |
| August 22, 2017 Filed Aug 23, 2017 20:21 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 3,473 | $477.52 | $1,658,426.96 |
DisclosureSEC source: 0001708138-17-000017 · edgardoc.xml · nonDerivative · entry 11 VAGELOS P ROY · CIK 0001013064 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 342,160 F11 · price: Represents volume-weighted average price of sales of 3,473 shares of Company stock on August 22, 2017 at prices ranging from $477.00 to $477.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 22, 2017 at each separate price. Read SEC document |
| August 22, 2017 Filed Aug 23, 2017 20:21 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 5,744 | $476.46 | $2,736,786.24 |
DisclosureSEC source: 0001708138-17-000017 · edgardoc.xml · nonDerivative · entry 10 VAGELOS P ROY · CIK 0001013064 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 345,633 F10 · price: Represents volume-weighted average price of sales of 5,744 shares of Company stock on August 22, 2017 at prices ranging from $476.01 to $476.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 22, 2017 at each separate price. Read SEC document |
| August 22, 2017 Filed Aug 23, 2017 20:21 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 5,610 | $475.49 | $2,667,498.90 |
DisclosureSEC source: 0001708138-17-000017 · edgardoc.xml · nonDerivative · entry 9 VAGELOS P ROY · CIK 0001013064 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 351,377 F9 · price: Represents volume-weighted average price of sales of 5,610 shares of Company stock on August 22, 2017 at prices ranging from $475.00 to $475.94. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 22, 2017 at each separate price. Read SEC document |
| August 22, 2017 Filed Aug 23, 2017 20:21 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 2,400 | $474.64 | $1,139,136.00 |
DisclosureSEC source: 0001708138-17-000017 · edgardoc.xml · nonDerivative · entry 8 VAGELOS P ROY · CIK 0001013064 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 356,987 F8 · price: Represents volume-weighted average price of sales of 2,400 shares of Company stock on August 22, 2017 at prices ranging from $474.00 to $474.91. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 22, 2017 at each separate price. Read SEC document |
| August 22, 2017 Filed Aug 23, 2017 20:21 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 200 | $473.65 | $94,730.00 |
DisclosureSEC source: 0001708138-17-000017 · edgardoc.xml · nonDerivative · entry 7 VAGELOS P ROY · CIK 0001013064 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 359,387 F7 · price: Represents volume-weighted average price of sales of 200 shares of Company stock on August 22, 2017 at prices ranging from $473.55 to $473.75. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 22, 2017 at each separate price. Read SEC document |
| August 22, 2017 Filed Aug 23, 2017 20:21 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 900 | $472.67 | $425,403.00 |
DisclosureSEC source: 0001708138-17-000017 · edgardoc.xml · nonDerivative · entry 6 VAGELOS P ROY · CIK 0001013064 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 359,587 F6 · price: Represents volume-weighted average price of sales of 900 shares of Company stock on August 22, 2017 at prices ranging from $472.38 to $472.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 22, 2017 at each separate price. Read SEC document |
| August 22, 2017 Filed Aug 23, 2017 20:21 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 600 | $471.63 | $282,978.00 |
DisclosureSEC source: 0001708138-17-000017 · edgardoc.xml · nonDerivative · entry 5 VAGELOS P ROY · CIK 0001013064 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 360,487 F5 · price: Represents volume-weighted average price of sales of 600 shares of Company stock on August 22, 2017 at prices ranging from $471.16 to $471.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 22, 2017 at each separate price. Read SEC document |
| August 22, 2017 Filed Aug 23, 2017 20:21 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 400 | $470.64 | $188,256.00 |
DisclosureSEC source: 0001708138-17-000017 · edgardoc.xml · nonDerivative · entry 4 VAGELOS P ROY · CIK 0001013064 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 361,087 F4 · price: Represents volume-weighted average price of sales of 400 shares of Company stock on August 22, 2017 at prices ranging from $470.50 to $470.84. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 22, 2017 at each separate price. Read SEC document |
| August 21, 2017 Filed Aug 23, 2017 20:21 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 200 | $472.16 | $94,432.00 |
DisclosureSEC source: 0001708138-17-000017 · edgardoc.xml · nonDerivative · entry 3 VAGELOS P ROY · CIK 0001013064 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 361,487 F3 · price: Represents volume-weighted average price of sales of 200 shares of Company stock on August 21, 2017 at prices ranging from $472.08 to $472.24 Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 21, 2017 at each separate price. Read SEC document |
| August 21, 2017 Filed Aug 23, 2017 20:21 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,951 | $471.09 | $919,096.59 |
DisclosureSEC source: 0001708138-17-000017 · edgardoc.xml · nonDerivative · entry 2 VAGELOS P ROY · CIK 0001013064 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 361,687 F2 · price: Represents volume-weighted average price of sales of 1,951 shares of Company stock on August 21, 2017 at prices ranging from $471.00 to $471.86. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 21, 2017 at each separate price. Read SEC document |
| August 21, 2017 Filed Aug 23, 2017 20:21 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 22,118 | $470.23 | $10,400,547.14 |
DisclosureSEC source: 0001708138-17-000017 · edgardoc.xml · nonDerivative · entry 1 VAGELOS P ROY · CIK 0001013064 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 363,638 F1 · price: Represents volume-weighted average price of sales of 22,118 shares of Company stock on August 21, 2017 at prices ranging from $470.00 to $470.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 21, 2017 at each separate price. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.